Hinge Health’s (HNGE) “Overweight” Rating Reiterated at Piper Sandler

Hinge Health (NYSE:HNGE)‘s stock had its “overweight” rating reissued by stock analysts at Piper Sandler in a note issued to investors on Wednesday,Benzinga reports. They presently have a $71.00 price objective on the stock, up from their previous price objective of $70.00. Piper Sandler’s target price indicates a potential upside of 51.88% from the company’s current price.

Several other research analysts have also issued reports on HNGE. Robert W. Baird assumed coverage on Hinge Health in a research note on Friday, September 5th. They set a “neutral” rating and a $56.00 price objective for the company. Morgan Stanley increased their target price on Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a report on Tuesday, September 23rd. Citigroup assumed coverage on Hinge Health in a report on Monday, July 14th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Hinge Health in a report on Wednesday, October 8th. Finally, JMP Securities increased their target price on Hinge Health from $58.00 to $65.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $59.67.

Hinge Health Stock Down 12.5%

Shares of HNGE stock traded down $6.69 during trading hours on Wednesday, reaching $46.75. 1,713,116 shares of the company’s stock were exchanged, compared to its average volume of 989,439. Hinge Health has a fifty-two week low of $33.42 and a fifty-two week high of $62.18. The business’s fifty day simple moving average is $53.18.

Hinge Health (NYSE:HNGE) last issued its earnings results on Tuesday, November 4th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.18. The firm had revenue of $154.21 million during the quarter, compared to analyst estimates of $142.44 million. The business’s revenue for the quarter was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Institutional Investors Weigh In On Hinge Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Hinge Health in the third quarter valued at about $37,000. Montag A & Associates Inc. acquired a new stake in shares of Hinge Health in the second quarter valued at about $41,000. Jones Financial Companies Lllp increased its stake in shares of Hinge Health by 348.0% in the third quarter. Jones Financial Companies Lllp now owns 1,120 shares of the company’s stock valued at $54,000 after buying an additional 870 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Hinge Health in the second quarter valued at about $48,000. Finally, Lisanti Capital Growth LLC increased its stake in shares of Hinge Health by 2.0% in the third quarter. Lisanti Capital Growth LLC now owns 60,911 shares of the company’s stock valued at $2,990,000 after buying an additional 1,211 shares during the period.

Hinge Health Company Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.